![](/img/cover-not-exists.png)
A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma®5% DIF, the Next Generation of Flebogamma®
Melvin Berger, The Flebogamma® 5% DIF InvestigatorsVolume:
27
Language:
english
Pages:
6
DOI:
10.1007/s10875-007-9107-x
Date:
November, 2007
File:
PDF, 126 KB
english, 2007